Erythrocyte Complement Receptor 1 and Alzheimer Disease

The recruitment status of this study is unknown because the information has not been verified recently.

Verified March 2012 by CHU de Reims.
Recruitment status was Recruiting

Sponsor:

Information provided by (Responsible Party):

CHU de Reims

ClinicalTrials.gov Identifier:

NCT01565434

First received: March 26, 2012

Last updated: March 27, 2012

Last verified: March 2012

History of Changes

Purpose

Main objective: investigate whether a functional polymorphism of CR1 (length, number of binding sites in C4b C3b, erythrocyte density, rate of soluble CR1 ...) so determined genetic or acquired, is a susceptibility factor for the disease Alzheimer's.

Condition	Intervention
Alzheimer Disease	Other: CR1 impact


Study Type:	Interventional
Study Design:	Primary Purpose: Screening

Resource links provided by NLM:

Genetics Home Reference related topics: Alzheimer disease

MedlinePlus related topics: Alzheimer's Disease

Genetic and Rare Diseases Information Center resources: Alzheimer Disease Familial

U.S. FDA Resources

Further study details as provided by CHU de Reims:


Estimated Enrollment:	200
Study Start Date:	February 2012

Eligibility


Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	Yes

Criteria

Inclusion Criteria:

caucasians people with a Alzheimer dementia defined on DSMIV criteria for patients and without Alzheimer disease for control subjects

Exclusion Criteria:

diseases modifying CR1 physiology

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01565434

Contacts


Contact: Rachid MAHMOUDI, MD		rmahmoudi@chu-reims.fr

Locations


France
CHU de REIMS	Recruiting
Reims, France, 51092
Contact: Rachid MAHMOUDI, MD rmahmoudi@chu-reims.fr
Principal Investigator: Rachid MAHMOUDI, MD

Sponsors and Collaborators

CHU de Reims

More Information

No publications provided


Responsible Party:	CHU de Reims
ClinicalTrials.gov Identifier:	NCT01565434 History of Changes
Other Study ID Numbers:	REIMS-AOL2011-01
Study First Received:	March 26, 2012
Last Updated:	March 27, 2012
Health Authority:	France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)

Additional relevant MeSH terms:


Alzheimer Disease Brain Diseases Central Nervous System Diseases Delirium, Dementia, Amnestic, Cognitive Disorders Dementia	Mental Disorders Nervous System Diseases Neurodegenerative Diseases Tauopathies

ClinicalTrials.gov processed this record on March 02, 2015

To Top